vTv Therapeutics Inc. $VTVT

What the company doesAI summary of filing

vTv Therapeutics is a late-stage biopharmaceutical company developing orally administered therapies for metabolic and inflammatory diseases. Its lead product, cadisegliatin (TTP399), a liver-selective glucokinase activator, is currently in Phase 3 clinical trials as a potential oral adjunctive therapy to insulin for type 1 diabetes; the company received FDA Breakthrough Therapy designation for this indication in 2021 and resumed the Phase 3 CATT1 trial in 2025 after a temporary clinical hold was lifted in March 2025. The company is pre-revenue and funds development through private placements and partnership agreements, including a $20 million upfront payment from amending its license agreement with Newsoara BioPharma for global rights to its PDE4 inhibitor HPP737. vTv also maintains a pipeline of earlier-stage programs including a GLP-1 receptor agonist (TTP273), RAGE antagonist (TTP-RA), PPAR-δ agonist (HPP593), and Nrf2/Bach1 modulators, along with partnered programs including azeliragon with Cantex Pharmaceuticals. [10-K 2026-03-10]

Segments: Cadisegliatin (TTP399) - glucokinase activator for type 1 diabetes, TTP273 - GLP-1 receptor agonist, HPP737 - PDE4 inhibitor (partnered with Newsoara), Azeliragon - RAGE antagonist (partnered with Cantex)